Wed, Jul 8, 2026
[Archive]
Articles In Press
Back to the articles list |
Back to browse issues page
Hayder Ahmed Sahar Algburi1 
, Ahmad Deylami2 , Hadis Musavi3 , Hossein Mokhtari4 , Neda Masoumi Qajari5 , Fatemeh Lotfi Asrami6 , Abbas Khonakdar *7
, Ahmad Deylami2 , Hadis Musavi3 , Hossein Mokhtari4 , Neda Masoumi Qajari5 , Fatemeh Lotfi Asrami6 , Abbas Khonakdar *7
1- 1Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2- Department of Urology, School of Medicine, Mazandaran University of Medical Sciences
3- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4- 3Amol faculty of paramedicine, Mazandaran university of medical sciences, Sari, Iran
5- Genetic biology,Tonekabon Islamic Azad University,Tnekabon,Iran
6- 5Department of Biochemistry, Biophysics, Genetics and Nutrition, School of Medicine Metabolic Disorders Research Center, Golestan University of Medical Sciences
7- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran & Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical
2- Department of Urology, School of Medicine, Mazandaran University of Medical Sciences
3- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4- 3Amol faculty of paramedicine, Mazandaran university of medical sciences, Sari, Iran
5- Genetic biology,Tonekabon Islamic Azad University,Tnekabon,Iran
6- 5Department of Biochemistry, Biophysics, Genetics and Nutrition, School of Medicine Metabolic Disorders Research Center, Golestan University of Medical Sciences
7- Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran & Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical
Abstract: (314 Views)
Background: Differentiating Prostate Cancer (PC) from benign prostatic hyperplasia (BPH) remains clinically challenging due to overlapping symptoms and biomarker alterations. This study compared biochemical, hematological, and inflammatory markers in both conditions to assess their potential diagnostic value.
Methods: A cross-sectional study was performed on 40 patients with PC and 120 patients with benign prostatic hyperplasia. The measurement of biochemical parameters included complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and total and free prostate-specific antigen (PSA). The process involved statistical comparisons, ROC analysis, and correlation tests
Results: Compared to BPH, patients with PC had significantly higher PSA (free and total), CRP, and lymphocyte counts (All p<0.05). Despite the diagnostic utility of PSA and inflammatory markers (AUCs 0.68-0.80), hematological parameters in isolation were not strong discriminators (AUCs<0.50), and a combined biomarker strategy would be more effective in clinical discrimination.
Conclusion: Detection of PC from BPH is accurately achieved by examining elevated free and total PSA levels, along with increased systemic inflammation, as indicated by CRP. The independent discriminant value of hematologic parameters is limited despite significant diversity between groups.. A combination of PSA and inflammatory markers in a two-biomarker strategy can improve clinical discrimination and reduce inappropriate therapy.
Methods: A cross-sectional study was performed on 40 patients with PC and 120 patients with benign prostatic hyperplasia. The measurement of biochemical parameters included complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and total and free prostate-specific antigen (PSA). The process involved statistical comparisons, ROC analysis, and correlation tests
Results: Compared to BPH, patients with PC had significantly higher PSA (free and total), CRP, and lymphocyte counts (All p<0.05). Despite the diagnostic utility of PSA and inflammatory markers (AUCs 0.68-0.80), hematological parameters in isolation were not strong discriminators (AUCs<0.50), and a combined biomarker strategy would be more effective in clinical discrimination.
Conclusion: Detection of PC from BPH is accurately achieved by examining elevated free and total PSA levels, along with increased systemic inflammation, as indicated by CRP. The independent discriminant value of hematologic parameters is limited despite significant diversity between groups.. A combination of PSA and inflammatory markers in a two-biomarker strategy can improve clinical discrimination and reduce inappropriate therapy.
Type of Study: Original Research Article |
Subject:
Clinical Medicine
Received: 2025/08/22 | Accepted: 2026/04/12
Received: 2025/08/22 | Accepted: 2026/04/12
References
1. Tang X, Liu Z, Ren J, Cao Y, Xia S, Sun Z, et al. Comparative RNA-sequencing analysis of the prostate in a mouse model of benign prostatic hyperplasia with bladder outlet obstruction. Molec Cell Biochem. 2023;478(12):2721-37. [DOI:10.1007/s11010-023-04695-2] [PMID] [PMCID]
2. Chen X, Yang S, He Z, Chen Z, Tang X, Lin Y, et al. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025;15(1):5644. [DOI:10.1038/s41598-025-90229-3] [PMID] [PMCID]
3. Rawla P. Epidemiology of prostate cancer. W J Oncol. 2019;10(2):63. [DOI:10.14740/wjon1191] [PMID] [PMCID]
4. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J Urol. 2021;206(4):806-17. [DOI:10.1097/JU.0000000000002184] [PMID]
5. Merriel SW, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):54. [DOI:10.1186/s12916-021-02230-y] [PMID] [PMCID]
6. Bhindi A, Bhindi B, Kulkarni GS, Hamilton RJ, Toi A, van der Kwast TH, et al. Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. Canadian Urol Assoc J. 2017;11(1-2):41. [DOI:10.5489/cuaj.4031] [PMID] [PMCID]
7. Cicione A, Cormio L, Cantiello F, Palumbo IM, De Nunzio C, Lima EARd, et al. Presence and severity of lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy. Minerva Urol Nephrol. 2017;69(5):486-92 [DOI:10.23736/S0393-2249.17.02737-0] [PMID]
8. Chen Y, Yan H, Xu Y, Chen K, Yang R, Yang J, et al. Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer. Disc Oncol. 2025;16(1):13. [DOI:10.1007/s12672-025-01760-8] [PMID] [PMCID]
9. Oruqi M, Krasniqi B, Gashi H, Neziri A, Podvorica E. Relationship between age, prostate size, and Prostate-Specific Antigen (PSA) role in patients with Benign Prostatic Hyperplasia (BPH). Onkol Radioter. 2024;18(4).
10. Leboutte F, Schykowski T, Van de Plas J, Lemmer O, Neisius A. Retrospective, single center evaluation of transperineal prostate biopsy omitting antibiotic prophylaxis and omitting periinterventional screening for bacteriuria. W J Urol. 2025;43(1):378. [DOI:10.1007/s00345-025-05672-8] [PMID] [PMCID]
11. Gravestock BP, Matthew MSh, BM B, Veeratterapillay MR, Heer BR. Prostate cancer diagnosis: In: Urologic Cancers [Internet]. Brisbane (AU): Exon Publications; 2022. Chapter 12. [DOI:10.36255/exon-publications-urologic-cancers-prostate-cancer-biopsy] [PMID]
12. Mukhiya GK, Mukhiya GW, Jain N, Jain M, Mukhiya K. Predicting significance of blood parameters in diagnosis of prostate carcinoma in a tertiary center in Udaipur, Rajasthan. J Clin Diag Res. 2021;15(4). [DOI:10.7860/JCDR/2021/48409.14773]
13. Shi C, Cao H, Zeng G, Yang L, Wang Y. The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001-2008. Plos one. 2024;19(7):e0306860. [DOI:10.1371/journal.pone.0306860] [PMID] [PMCID]
14. Mensah-Bonsu YA, Appiah KAA, Dedjoe V, Djankpa FT, Ainooson GK, Ntim EA. Ratios of prostate-specific antigen to albumin, C-reactive protein, and haemoglobin concentration are valuable markers to predict patients with either prostate cancer or benign prostate hyperplasia. 2024. PREPRINT (Version 1) available at Research Square [
https://doi.org/10.21203/rs.3.rs-4326102/v1 [DOI:10.21203/rs.3.rs-4326102/v1]]
15. Yu S, Zhang C, Zhang W, Qian C, Tong X, Yuan H. Study on the clinical application value of serum inflammatory markers in benign prostatic hyperplasia. Clin Lab. 2025;71(1). [DOI:10.7754/Clin.Lab.2024.240607]
16. Guo P, Garu A, Chen T, Guo Y, Tang Y, Pan J, et al. A hematological and inflammatory marker-based model for prostate carcinoma diagnosis. Am J Cancer Res. 2025;15(6):2551. [DOI:10.62347/TVFQ4646] [PMID] [PMCID]
17. Wang H, Tang R, Luo S, Hou H, Liu J, Liu M, et al. Association of life's crucial 9 score with benign prostatic hyperplasia: a cross-sectional study. J Health Popul Nutr. 2025;44(1):163. [DOI:10.1186/s41043-025-00925-z] [PMID] [PMCID]
18. Navarro RE, González-Padilla DA, Subiela JD, Pérez-Serrano C, Olmos D, Carlsson SV. Prostate cancer screening. Asian J Urol. 2024.
19. Sajadi A, Nooraei M, Ghorbani A, Alimohammadian M, Zahedi M-J, Darvish MS, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry.Arch Iran Med. 2007;10(4):481-5
20. Ayyıldız SN, Benli E, Çırakoğlu A, Ayyıldız A. Comparison of serum c-reactive protein levels between benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy.New J Urol.2016;11(3):10-15
21. Islam MA, Islam SS, Haque MJ, Hossain MM. Ability of free/total serum PSA ratio in diagnosing prostate cancer and benign prostatic hyperplasia. J Teach Assoc. 2023;36(2):101-9. [DOI:10.3329/taj.v36i2.71537]
22. Coradduzza D, Sibono L, Tedde A, Marra S, De Miglio MR, Zinellu A, et al. Diagnostic stratification of prostate cancer through blood-based biochemical and inflammatory markers. Diagnostics. 2025;15(11):1385. [DOI:10.3390/diagnostics15111385] [PMID] [PMCID]
23. Guo P , A G , Chen T , Guo Y , Tang Y , Pan J ,et al. A hematological and inflammatory marker-based model for prostate carcinoma diagnosis.Am J Cancer Res.2025;15(6):2251-63 [DOI:10.62347/TVFQ4646] [PMID] [PMCID]
24. Mehta S, Ketkar M, Jain D. Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting carcinoma prostate (CaP) in patients with lower urinary tract symptoms and raised serum prostate-specific antigen (sr. PSA). Med J Arm Forc India. 2024;80:S160-S6. [DOI:10.1016/j.mjafi.2023.03.001] [PMID] [PMCID]
25. Yun J, Lee H, Yang W. Association between systemic inflammation and serum prostate-specific antigen in a healthy Korean population. Turk J Urol. 2017;43(3):284. [DOI:10.5152/tud.2017.25901] [PMID] [PMCID]
26. Sun Z, Ju Y, Han F, Sun X, Wang F. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer. J Clin Lab Analysis. 2018;32(3):e22277. [DOI:10.1002/jcla.22277] [PMID] [PMCID]
27. Liu T, Zhuo L. [Retracted] The role of C‐reactive protein in the prognosis of prostate cancer: A meta‐analysis. J Environ Public Health. 2023;2023(1):6222324. [DOI:10.1155/2023/6222324] [PMID] [PMCID]
28. Tang L, Li X, Wang B, Luo G, Gu L, Chen L, et al. Prognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysis. PloS one. 2016;11(4):e0153981. [DOI:10.1371/journal.pone.0153981] [PMID] [PMCID]
29. Tang Z, Li S, Zeng M, Zeng L, Tang Z. The association between systemic immune-inflammation index and prostate-specific antigen: results from NHANES 2003-2010. PLoS One. 2024;19(11):e0313080. [DOI:10.1371/journal.pone.0313080] [PMID] [PMCID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Farname Inc. is licensed under CC BY-NC 4.0
